History
Here is our journey so far
- 2021.02
- Launched CT-P59, an antibody treatment for Covid-19
- 2021.02
- Launched RemsimaSC, an autoimmune disease medicine
- 2020.12
- Completed the construction of the PFS manufacture lines
- 2019.08
- Released the first batch of chemical pharmaceuticals for export to the US
- 2019.08
- Groundbreaking ceremony for the PFS manufacture lines
- 2019.04
- Merged Celltrion Chemical Institute
- 2019.02
- Obtained the EU-GMP for the MHRA, UK
- 2018.01
- Obtained the US FDA cGMP for the Cheongju Plant
- 2017.04
- Launched Herzuma, a breast cancer/gastric cancer medicine
- 2017.02
- Launched Truxima, a blood cancer medicine
- 2015.08
- Obtained KGMP for the Cheongju Plant
- 2015.04
- Relocated the head office to Ochang-eup, Cheongwon-gu, Cheongju-si, Chungcheongbuk-do
- 2014.12
- Completed the construction of the Cheongju Plant (2nd Industrial Complex, Ochang, Chungcheongbuk-do)
- 2012.09
- Launched Remsima, an autoimmune disease medicine
- 2010.10
- Broke ground for the Cheongju Plant project (2nd Industrial Complex, Ochang, Chungcheongbuk-do)
- 2009.07
- Became a part of the Celltrion Group